People · Operator
Named in public records as an officer, director or promoter · active 2008–2021 · Biotechnology, Pharmaceuticals, Other Technology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grail, Inc. | — | Biotechnology | Growth/Late | $2.2B | $2.9B | 2019 |
| Juno Therapeutics, Inc. | — | Biotechnology | Growth/Late | $1.1B | $1.3B | 2014 |
| Lyell Immunopharma, Inc. | — | Pharmaceuticals | Growth/Late | $493.0M | $17.9B | 2020 |
| Sonoma Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $265.0M | $7.7B | 2021 |
| Immune Design Corp. | — | Biotechnology | Series C | $144.6M | $2.0B | 2008 |
| Mindstrong, Inc. | — | Other Technology | Series B | $52.0M | $944.1M | 2017 |
| Medical Creations, Inc. | — | Healthtech | Series A | $17.9M | $122.5M | 2018 |
Richard Klausner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Klausner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 3 | 22 |
| Hans Bishop | 3 | 3 |
| Catherine Friedman | 2 | 3 |
| Hemant Taneja | 1 | 21 |
| Robert Epstein | 1 | 8 |
| Scott Ward | 1 | 7 |
| Robert Nelson | 1 | 7 |
| Brian Atwood | 1 | 6 |
| Anthony Evnin | 1 | 6 |
| MIN CUI | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| William Rastetter | 1 | 4 |
| Jim Tananbaum | 1 | 4 |
| Terry Rosen | 1 | 4 |
| Fan Yu | 1 | 4 |
| Tom Insel | 1 | 3 |
| James Paul Rickey | 1 | 3 |
| Stephen Hill | 1 | 3 |
| Mark Frohlich | 1 | 3 |
| Mary Agnes Wilderotter | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.